Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
139,000
-9,800 (-6.59%)
At close: Feb 6, 2026
358.75%
Market Cap4.22T +364.1%
Revenue (ttm)7.75B -44.9%
Net Income-21.89B
EPS-728.12
Shares Out30.36M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume262,872
Average Volume322,902
Open141,000
Previous Close148,800
Day's Range133,900 - 143,400
52-Week Range25,450 - 179,900
Beta1.37
RSI58.14
Earnings DateMar 18, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 18
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.

Financial Statements